Abstract | BACKGROUND: METHODS: The initial dosage was 0.075 mg/kg/day for 14 days every 28 days and was increased or decreased by 0.025-mg/kg/day increments at each subsequent cycle until the maximum tolerated dose (MTD) was achieved. RESULTS: All patients were fully assessable. One (4%) patient had a complete response, 5 (17%) had a partial response, 13 (50%) had stabilized disease, and 10 (34%) had progressive disease. The treatment-limiting toxic effect was diarrhea, and the median tolerated dosage was 0.1 mg/kg/day for 14 days every 28 days (range, 0.05-0.275 mg/kg/day). Five of the six responses occurred at a dosage of 0.1 mg/kg/day or less, which was achievable in most patients. Patients who reached their MTD without achieving a complete or partial response were switched to circadian-infusion floxuridine to determine whether an increased dose intensity could be administered and whether this would translate into additional responses. A higher median tolerated dosage of 0.15 mg/kg/day was achieved with circadian administration; however, no additional responses were observed. The median survival time was 891 days after the diagnosis of metastatic RCC and 445 days after the institution of floxuridine therapy. CONCLUSIONS: Constant-infusion floxuridine is active against metastatic RCC and produces a response rate that appears to be comparable to that of circadian administration of floxuridine.
|
Authors | M J Wilkinson, J W Frye, E J Small, A P Venook, P R Carroll, M L Ernest, R J Stagg |
Journal | Cancer
(Cancer)
Vol. 71
Issue 11
Pg. 3601-4
(Jun 01 1993)
ISSN: 0008-543X [Print] United States |
PMID | 8490909
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Carcinoma, Renal Cell
(drug therapy, secondary)
- Circadian Rhythm
- Diarrhea
(chemically induced)
- Drug Administration Schedule
- Female
- Floxuridine
(administration & dosage, adverse effects)
- Humans
- Infusion Pumps, Implantable
- Infusions, Intravenous
- Kidney Neoplasms
(drug therapy)
- Male
- Middle Aged
|